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Abstract: Oral cancer is one of the 10 most common cancers in the world, with a delayed clinical detection, poor 
prognosis, without specific biomarkers for the disease and expensive therapeutic alternatives. This review aims to 
present the fundamental aspects of this cancer, focused on squamous cell carcinoma of the oral cavity (OSCC), 
moving from its definition and epidemiological aspects, addressing the oral carcinogenesis, oral potentially malig-
nant disorders, epithelial precursor lesions and experimental methods for its study, therapies and future challeng-
es. Oral cancer is a preventable disease, risk factors and natural history is already being known, where biomedical 
sciences and dentistry in particular are likely to improve their poor clinical indicators.
Keywords: Mouth neoplasms, oral cancer, oral squamous cell carcinoma, carcinogenesis, neoplasm staging, tu-
mor microenvironment
Introduction
Oral cancer is a highly relevant problem of glob-
al public health, especially for dental surgeons. 
It is located within the top 10 ranking incidence 
of cancers and despite the progress in research 
and therapy, survival has not improved signifi-
cantly in the last years, representing a continu-
ing challenge for biomedical science. This 
paper aimed to report key aspects of this can-
cer, integrating clinical, histological and molec-
ular concepts for a better understanding of 
their biological pathways, allowing the reader 
and researcher construct a map which could 
serve to place and integrate this growing 
information.
Definition
Oral cancer is a malignant neoplasia which aris-
es on the lip or oral cavity. Is traditionally 
defined as a squamous cell carcinoma (OSCC), 
because in the dental area, 90% of cancers are 
histologically originated in the squamous cells 
[1]. It has different levels of differentiation and 
a propensity for lymph node metastasis [2].
Epidemiology
Oral cancer is two to three times more preva-
lent in men than women in most ethnic groups 
[http://seer.cancer.gov/statfacts/html/oralcav.
html]. In worldwide reports, cancers of all 
regions of the oral cavity and pharynx are 
grouped and collectively represent the sixth 
most common cancer in the world [3]. According 
to the latest reports of the International Agency 
for Research on Cancer (IARC) for oral cancer 
(ICD-10 code C00-08: Lip, Oral Cavity) which 
includes lips, tongue, gingiva, mouth floor, 
parotid and salival glands, annual incidence is 
higher around the world, which is over 300.000 
diagnosed cases, and the annual mortality is 
about 145,000 death [http://globocan.iarc.fr/
Pages/summary_table_pop_sel.aspx]. Table 1 
shows the incidence and mortality for oral can-
cer according to the regions of the World Health 
Organization (WHO), and those that present the 
most critical numbers are WHO South-East Asia 
region (SEARO) and WHO Europe region (EURO). 
Specifically by area, those that are character-
ized by a high incidence of oral cancer are found 
in South and Southeast Asia (Sri Lanka, India, 
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Pakistan and Taiwan), areas of the West 
(France) and Eastern Europe (Hungary, Slovakia 
and Slovenia), Latin America and the Caribbean 
(Brazil, Uruguay and Puerto Rico) and Pacific 
regions (Papua New Guinea and Melanesia) [3]. 
The incidence also varies according to the 
Human development index of the United 
Nations Development Programme (UNDP). 
According to this index, incidence is higher in 
countries with better development indicators 
(Table 1). The GLOBOCAN grouping shows that 
the crude rate and age-standardized incidence 
rate (worldwide) are higher in more developed 
regions, but mortality is higher in less devel-
oped areas, which shows social inequality.
Risk factors
Oral cancer is a preventable disease, where 
smoking and alcohol-considered major risk fac-
tors-are present in 90% of cases [4], having 
them both a synergic effect [5].
Tobacco
In 2007 the IARC concluded that “there is quite 
evidence to establish that snuff smoke is carci-
nogenic, and for example, it causes cancer of 
the oral cavity and pancreas” [6]. The risk for 
developing oral cancer is 3 times higher in 
smokers compared with nonsmokers [7]. Be- 
sides, the risk for oral cancer is 35% lower in 
people who quit smoking four years ago than 
those who continue smoking, and not higher in 
persons with no smoking antecedents for over 
20 years when compared with people who have 
never smoked [8]. An environment with ciga-
rette smoke is also risky; the risk for oral can-
cer is 87% higher in those who never smoked, 
but were exposed to an environment with ciga-
rette smoke (involuntary smoking) compared 
with those who never smoked and not have 
been exposed [9]. Cigarette smoke weakens 
immunity in the oral cavity by promoting gingivi-
Table 1. GLOBOCAN cancer incidence and mortality, all ages, both sexes by population
Incidence
Population Numbers Crude rate ASR (W) Accumulative risk
WHO African Region (AFRO) 13,484 1.5 2.7 0.30
WHO Americas Region (PAHO) 49,200 5.2 4.1 0.48
WHO East Mediterranean Region (EMRO) 20,681 3.3 4.6 0.52
WHO Europe Region (EURO) 65,933 7.3 4.6 0.53
WHO South-East Asia Region (SEARO) 103,464 5.6 6.4 0.73
WHO Western Pacific Region (WPRO) 47,524 2.6 2.0 0.22
UNDP Very High Human Development 92,338 8.0 4.8 0.54
UNDP Low Human Development 40,954 3.1 5.2 0.59
GLOBOCAN More Developed Regions* 100,823 8.1 4.7 0.54
GLOBOCAN Less Developed Regions* 199,550 3.4 3.7 0.42
Mortality
Numbers Crude rate ASR (W) Accumulative risk
WHO African Region (AFRO) 8,530 1.0 1.8 0.20
WHO Americas Region (PAHO) 12,803 1.3 1.0 0.12
WHO East Mediterranean Region (EMRO) 10,997 1.8 2.5 0.30
WHO Europe Region (EURO) 25,202 2.8 1.7 0.19
WHO South-East Asia Region (SEARO) 65,734 3.5 4.1 0.48
WHO Western Pacific Region (WPRO) 22,068 1.2 0.9 0.09
UNDP Very High Human Development 26,970 2.3 1.2 0.14
UNDP Low Human Development 25,238 1.9 3.3 0.39
GLOBOCAN More Developed Regions* 33,313 2.7 1.4 0.16
GLOBOCAN Less Developed Regions* 11,2040 1.9 2.1 0.24
WHO, World Health Organization; UNDP, United Nations Development Programme; GLOBOCAN Global Burden of Cancer Study 
2012. *The designation for more developed and less developed regions are intended for statistical convenience and do not 
necessarily express a judgment about the stage reached by a particular country or area in the development process. More 
developed regions: all regions of Europe plus Northern America, Australia/New Zealand and Japan. Less developed regions: 
all regions of Africa, Asia (excluding Japan), Latin America and the Caribbean, Melanesia, Micronesia and Polynesia. ASR (W), 
World age-specific rates.
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tis, periodontitis and oral cancer [10]. This 
smoke contains several elements that promote 
cancer and they basically can be grouped into 
three distinct groups: nitrosamines, benzopy-
renes and aromatic amines. These chemicals 
are called pre-carcinogens, which must suffer 
coordinated alterations by oxidative enzumes, 
so that the final product becomes poor in elec-
trons and into an agent to be covalently bound 
to the DNA, generating an adduct mutated 
region [11]. In addition to oxidation, enzymatic 
or non-enzymatic metabolism can also produce 
carcinogens, such as free radicals, which have 
unpaired electrons that make them extremely 
reactive being capable of promoting mutations 
by complex mechanisms [11]. Snuff consump-
tion expose the oral epithelium to free radicals 
of oxygen and nitrogen that can affect antioxi-
dant defense mechanisms. Elevated levels of 
these free radicals are found in oral precancer 
and cancer [12].
Alcohol
Alcohol (ethanol) can act as a both locally and 
systemically risk factor: increased permeability 
of oral mucosa, dissolving lipids components of 
the epithelium, causing epithelial atrophy and 
interference in DNA synthesis and repair; it also 
has genotoxicity and mutagenic effects, caus-
ing decreased salivary flow, affects the liver's 
ability to deal with toxic or potentially carcino-
genic compounds, and their chronic use is 
associated with an impairment of innate and 
acquired immunity, resulting in increased sus-
ceptibility to infections and neoplasms [13].
Other factors
Among other risk factors, there is the human 
papillomavirus (mainly associated with carci-
noma of the oropharynx [14]) and ultraviolet 
radiation (UV). The IARC classifies human papil-
lomavirus 16 (HPV16) as a cause for cancers of 
Figure 1. OSCC multistep progress. The development of squamous cell carcinoma of the oral cavity is considered 
a complex multistep process. Normal oral mucosal keratinocytes are chronically exposed to risk factors, which 
can break the homeostasis and generate genetic instability. Key genetic alterations occurring in TP53, NOTCH1 
(Notch homolog 1, translocation-associated [Drosophila]), EGFR (epidermal growth factor receptor), CDKN2A (cy-
clin-dependent kinase inhibitor 2a) genes STAT3 (signal transducer and activator of transcription 3), Cyclin D1, Rb 
(retinoblastoma) plus LOH (loss of heterozygosity). The proliferation and uncontrolled growth, along with a battery 
discharge granted adaptive advantages over the surrounding cells, which promote local invasion and orchestrate a 
collaboration of the surrounding stromal cells. Among the factors secreted by tumor cells are MMP2 (matrix metal-
loproteinase 2), MMP9 (matrix metalloproteinase 9), MMP13 (matrix metalloproteinase 13), ROS (reactive oxygen 
species), VEGF (vascular endothelial growth factor), CXCL1 (chemokine [CXC motif] ligand 1), CXCL8 (chemokine 
[CXC motif] ligand 8), PDGF (platelet-derived growth factor), IL-8 (inteleukin 8), FGF-2 (fibroblast growth factor 2), 
TGF-β (transforming growth factor-β), TNF-α (tumor necrosis factor-α), IL-1 (inteleukin 1), GMCSF (granulocye-macro-
phage colony-stimulating factor). This microenvironment promotes cell adhesion loss (ex. E-cadherin) and facilitates 
epithelium mes enchymal transition (EMT), Vimentin and N-cadherin can be expressed in these cells. CAFs markers 
(tumor-associated fibroblasts) are α-SMA (α-smooth muscle actin) and integrin α6. Endothelins can contribute to 
pro-migratory paracrine signaling between CAFs and oral cancer cells. It also promotes CXCL1 and CXCL8 endothe-
lial cell proliferation and survival. Endothelial cells produce factors like EGF, which increase migration.
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the oral cavity and pharyngeal tonsils, and 
HPV18 as possible causes of oral cancer 
[http://monographs.iarc.fr/ENG/Classification/
index.php]. The most-common sites of HPV-
related head and neck squamous cell carcino-
ma (HNSCC) are the tonsils and base of tongue 
within the oropharynx, with a prevalence rate of 
75%; HPV-related HNSCC is rare in nonoropha-
ryngeal sites. The presence of HPV is an estab-
lished prognostic biomarker of favourable out-
come in locally advanced oropharyngeal can-
cers [15]. Evidence shows that HPV contributes 
to carcinogenesis by two virus-encoded pro-
teins: E6 protein promotes the degradation of 
p53 tumor suppressor gene product; E7 that 
promotes the degradation of the tumor sup-
pressor gene product pRb (retinoblastoma pro-
tein) [16], causing a deregulation of the cell 
cycle control, which also leads to an overex-
pression of the inhibitor of cyclin dependent 
kinase p16Ink4a [14]. Ultraviolet radiation, mainly 
the UVB is also involved in lip cancer.
Table 2. TNM Definitions for Oral Cancer*
Primary tumor (T)
TX Cannot be assessed
T0 No evidence of primary tumor
Tis Carcinoma in situ (CIS)
T1 Tumor 2 cm or less in greatest dimension
T2 Tumor more than 2 cm but not more than 4 cm in greatest dimension
T3 Tumor more than 4 cm in greatest dimension
T4a Moderately advanced local disease. Lip: Tumor invades through cortical bone, inferior alveolar nerve, floor of 
mouth, or skin (chin or nose).
Oral cavity: Tumor invades through cortical bone, into deep/extrinsic muscle of tongue (genioglossus,  
hyoglossus, palatoglossus, and styloglossus), maxillary sinus, or skin of face.
T4b Very advanced local disease. Lip and oral cavity: Tumor invades masticator space, pterygoid plates, or skull 
base; or encases internal carotid artery
Regional lymph nodes (N)
NX Cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension
N2 Metastasis as specified in N2a, 2b, 2c (see below)
N2a Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension
N2b Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension
N2c Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension
N3 Metastasis in a lymph node more than 6 cm in greatest dimension
Distant metastasis (M)
MX Distant metastasis cannot be assessed
M0 No distant metastasis
Clinical stages (T+N+M)
0 Tis N0 M0
I T1 N0 M0
II T2 N0 M0
III T3 (enough alone), T2 or T1 N1 M0
IV A T4a
T1, T2 or T3
N0 or N1
N2
M0
M0
IV B any T
T4b
N3
any N
M0
M0
IV C any T any N M1
*Modified of IARC (International agency for research on cancer) screening group (http://screening.iarc.fr/atlasoralclassiftnm.
php) 
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Microscopic and macroscopic aspects
Carcinogenesis
Clearly the OSCC develops over many years and 
during this period there are several neoplasical 
sites transforming and taking place in the oral 
cavity [17]. Oral carcinogenesis (Figure 1) is a 
highly complex multifactorial process that 
occurs when epithelial cells are affected by 
various genetic alterations [18], including key 
disorders on TP53, NOTCH1 (Notch homolog 1 
genes are translocation-associated [Droso- 
phila]), EGFR (epidermal growth factor recep-
tor), CDKN2A (cyclin-dependent kinase inhibi-
tor 2a), STAT3 (signal transducer and activator 
of transcription 3), Cyclin D1, Rb (retinoblasto-
ma) [19]. Probably oral carcinogenesis starts 
with the transformation of a limited number of 
normal keratinocytes. This transformation can 
be expressed via cytogenetic changes and epi-
genetic processes that modify the progression 
of the cell cycle, DNA repair mechanisms, cell 
differentiation and apoptosis, which may be 
caused by random mutation, by exposure to a 
variety of biological factors, carcinogens or 
errors in the DNA repair process [20], resulting 
in an unstable keratinocyte into a  pre-cancer-
ization field and leading to malignant neoplas-
tic changes [20], which can inherit these altera-
tions to their clones. Subsequently, selection 
pressures on the microenvironment of the oral 
mucosa may act on the heterogeneous clonal 
population, allowing perpetuate those cells 
with better tools and advantages of adaptabili-
ty, survival and proliferation above their normal 
neighboring cells [20, 21]. Tumorigenesis re- 
quires multiple essential elements: a limitless 
replicative potential, self-sufficiency in growth 
signals, lack of sensitivity to anti-growth sig-
nals, the ability to evade apoptosis, increased 
angiogenesis, invasion and metastasis [22]. 
Recent evidence supports that the biophysical 
and biochemical signs of tumor-associated into 
the extracellular matrix influence the essential 
characteristics of cancer and therefore are 
essential for malignancy [23].
Tumor microenvironment (TME)
For an effective approach to cancer, it should 
be considered as a disease that involves com-
plex interactions among a community of het-
erotypic cells, characterized by the original can-
cerous tissue, the newly formed tissue and 
cells surrounding it [24]. The TME of OSCC 
include cancer-associated fibroblasts (CAFs), 
immune cells and other supporting cells (Figure 
1). Oncogenic changes in gene expression pro-
files contribute to microenvironmental altera-
tions such as ROS accumulation, overproduc-
tion of cytokines and epithelial mesenchymal 
transition (EMT). CAFs are some of the most 
critical elements of TME, contributing to prolif-
eration, invasion and metastasis. The adaptive 
immune response is suppressed in OSCC 
through overexpression of cytokines, induced 
Figure 2. Opportunities for biomarkers in oral can-
cer. The “natural history” of oral cancer allows the 
study of different phases in the progression of ma-
lignancy. One opportunity is given by the generation 
of an etiologic field -influenced by risk factors “ex-
posome” and their interactions “interactome” that 
promotes a state of susceptibility. The passage of 
this state to canzerisable field gives another oppor-
tunity for research. With the diagnosis may emerge 
prognostic and predictive biomarkers. Figure modi-
fied from Rivera C. Opportunities for biomarkers 
with potential clinical use in oral cancer. Medwave. 
2015 Jul 20;15(6):e6186. doi: 10.5867/med-
wave.2015.06.6186.
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apoptosis by T cells and modifications in anti-
gen processing machinery [25]. The overex-
pression of cytokines assessments such as 
transforming growth factor-β (TGF-β), contrib-
ute to the EMT, immunosuppression, and the 
evolution of the CAFs. Inflammation and hypox-
ia are the dynamic forces of angiogenesis and 
altered metabolism [26]. OSCC uses the glyco-
lytic and oxidative metabolism to feed tumor 
genesis through mechanisms which are cou-
pled between regions of cancer cell (parenchy-
ma) and TME cells (stroma) [19].
Some markers for elements in OSCC tumor 
microenvironment are shown in Figure 1, 
including E-cadherin, cytokeratin, PD-L1, FasL 
Table 3. Some cellular lines for the study of OSCC
Line Clinical features Comments
Site Age Sex TNM stage
SCC4 Tongue 55 M T3N0M0 From a patient who had radiation and methotrexate treatment for the 
tumor for 16 months before the biopsy was taken for culture. Epithe-
lial cell morphology: weak colonies.
SCC9 Tongue 25 M T2N1 The patient who developed this line did not had treatment before the 
biopsy was taken (NRT). Compared to SCC25, SCC4 y CAL27, this 
line show a higher resistance to cisplatine. Epithelial cell morphol-
ogy: weak colonies.
SCC15 Tongue 55 M T4N1M0 NRT. Epithelial cell morphology: tight colonies.
SCC25 Tongue 70 M T1N1M0 NRT. Compared with SCC15, this line has a higher invasive potential. 
Epithelial cell morphology: tight colonies.
CAL27 Tongue 56 M - NRT, isolated from patient with PD-OSCC.
BHY Alveolus 52 M - Isolated from a patient with WD-OSCC of the lower alveolus, highly 
invasive to the mandibular bone and the muscle layer of the oral 
floor; however, it did not metastasize.
HN Soft palate 60 M - Isolated from a patient with MD-OSCC of the soft palate that metas-
tasized to cervical lymph nodes, lungs, and brain, but did not invade 
bone.
HSC-3 Lymph node 
metastasis
64 M - Obtained from Japan Health Science Research Resources Bank (To-
kyo, Japan). The primary tumor was on the tongue with lymph node 
metastasis, and was MD-OSCC.
HaCaT Skin - - - Human adult low calcium high temperature cells (HaCaT), are spon-
teneously transformed aneuploid immortal keratinocyte cell line from 
adult human skin that have the caracteristics of basal epidermal ke-
ratinocites. This cell line currently used as a non-tumorigenic control.
OSCC, oral squamous cell carcinoma; T, primary tumor; N, regional lymph nodes metastasis; M, distant metastasis, NRT, patient 
did not receive treatment before the biopsy: WD, well differentiated, MD, moderately differentiated; PD, poorly or undifferenti-
ated.
Table 4. Oral cancer key points
Conceptual framework
It is a preventable disease.
The most important risk factors are snuff and alcohol (chronic exposure), they have a synergistic effect.
Has higher occurrence in people over 50 years.
The genetic instability in keratinocytes allows tumor development.
The erythroplasia and leukoplakia disorders are usually related to oral cancer.
It occurs most frequently on the tongue, floor of the mouth and lower lip.
The diagnosis is confirmed by biopsy and histopathological analysis.
Is diagnosed in advanced clinical stages.
Treatment options include surgery, radiotherapy and chemotherapy.
Until today there are no specific biomarkers.
Population screening reduces mortality.
Oral cancer
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(OSCC); CD33, CD144, ALDH (cancer stem cells 
markers); N-cadherin, vimentin (EMT); α-SMA, 
integrin α6 (CAFs); CD4+CD25+FoxP3+ (T regula-
tory cells); CD8+, TCR, Fas, PD-1 (cytotoxic T 
cells), CD4+ (cytotoxic Th2 cells) and CD34+ 
(myeloid precursor cells) [19].
Potentially malignant disorders and dysplastic 
changes
The OSCC can be presented as a “natural his-
tory”, which originates from non-aberrant kera-
tinocytes which are chronically exposed to a 
stimulus that breaks its homeostasis, following 
an epithelial hyperplasia, dysplasia in different 
degrees, carcinoma in situ (CIS) and an inva-
sive carcinoma leading to the generation of dis-
tant metastases [17], with the consequent cli- 
nical manifestations. This natural history offers 
a map for the different research approaches in 
both basic science, translational and clinical-
therapeutic environment.
The first detectable clinical changes that can 
advise of an epithelium on its way to establish-
ing an OSCC are potentially the occurrence of 
malignant disorders, including leukoplakia and 
erythroplasia which are the most common ones 
[27]. Leukoplakia is a white plate uncertain 
risk, by excluding other diseases or disorders 
which are already known to not increase the 
risk for cancer [28]. Microscopically expensive 
exhibits several reactive epithelial changes 
such as hyperplasia, hyperkeratosis and acan-
thosis. Histologically, a distinction is essential 
to be made between dysplastic and non-dys-
plastic leukoplakia. The term refers to epithelial 
dysplasia precursor lesions showing cytology 
combinations and degrees of atypia (in exam-
ple, hyperchromatism, increased nuclear size, 
pleomorphism, dyskeratosis, abnormal mitotic 
figures or increased mitosis). When alterations 
occurs in the basal or parabasal keratinocytes, 
which is called mild dysplasia, the atypia found 
in the middle level is called moderate dyspla-
sia; when changes are extended to the surface 
layer, the terms advanced dysplasia and carci-
noma are applied in situ (atypia is complete, 
from the base to the surface) [16]. About 1% 
may progress to malignant transformation [27]. 
Besides white plates, there are red ones. 
Erythroplasia (high malignant potential) is 
defined as a red plate that cannot be character-
ized clinically or pathologically as other disease 
[27]. If a mixture of red and white change 
occurs, the lesions are called erythroleukopla-
kia. Erythroplakias commonly shows some 
degree of presence of dysplasia and carcino-
ma. In general, it should be treated because 
their high-risk malignant transformation [27].
In general, if a lesion in the oral mucosa does 
not heal within three weeks, a malignant tumor 
or some other serious condition should be 
excluded, indicating a biopsy and its histopath-
ological analysis [29].
Classification of tumors: WHO and gene-ex-
pression profile
The OSCC derived from an epithelial dysplasia 
and is characterized by a neoplastic prolifera-
tion mechanism which destroys oncogenic sub-
epithelial basement membrane locally [24]. 
The ability to metastasize is directly associated 
with the degree of tumor differentiation of the 
cancer cells [24]. The International Classifi- 
cation of Tumors of the WHO ranks well differ-
entiated tumors, moderately differentiated 
and poorly or undifferentiated [30]. Another fre-
quently studied histological feature is the front 
pattern of invasion (degree of cohesion 
between invading cancer cells), which is mea-
sured as a good prognostic factor in OSCC [4]. 
WHO classification is essentially histological 
and extremely limited. Since cancer is a com-
plex disease characterized by genetic heteroge-
neity, HNSCCs (including OSCC) can also be 
classified based on their gene-expression pro-
file as “basal”, “mesenchymal”, “atypical” and 
“classical”. The atypical subtype included most 
of the HPV-positive HNSCCs [15]. These sub-
types-added to HPV infection status- have been 
validated using independent datasets in The 
Genome Cancer Atlas (TGCA) reports [31]. The 
TCGA study represents the most comprehen-
sive integrative genomic analysis of HNSCCs.
Staging of oral cancer
The most common sites for the presentation of 
oral cancer are the tongue (ventral-lateral edge, 
40% of cases), floor of the mouth (30% of 
cases) and lower lip [16, 32, 33]. Regardless of 
the accessibility of the oral cavity during clinical 
examination, oral cancer is usually diagnosed 
in advanced stages. The most common rea-
sons for this are the initial misdiagnosis and 
ignorance of the patient or the treating profes-
sional [34], which evidently decreases the 
Oral cancer
11891 Int J Clin Exp Pathol 2015;8(9):11884-11894
chances of survival, despite therapeutic strate-
gies [24].
In the clinical-therapeutic field, most models 
take part in center their base decisions on clini-
cal and pathological information along with the 
health of the patient [24]. In OSCC, as in most 
other cancers, the prognosis depends largely 
on factors which are more related to lifestyle 
such as smoking, alcohol consumption, medi-
cal comorbidity and undeniably the step (stag-
ing) of tumor [35].
The TNM staging system (tumor-lymph node-
metastasis) is based on the best estimate of 
the extent of disease before treatment (Table 
2). Assessment of the primary tumor is based 
on inspection and palpation, where the proper 
nodal drainage areas are examined by careful 
palpation and also imaging studies can help 
in metastases [http://www.cancer.gov/cancer-
topics/pdq/treatment/lip-and-oral-cavity/Heal- 
thProfessional/page3]. But so far, the data 
delivered by the conventional TNM is insuffi-
cient to predict the response to nonsurgical 
treatment, which keeps the door permanently 
open to molecular studies in order to search for 
biomarkers. Information obtained from clinical 
examination and imaging are used to assign a 
clinical stage (cTNM), which is then used to 
stratify patients (clinical stage) for selection of 
therapeutic and report the results of treatment 
alternatives. The differentiation between local-
ized disease (stages I and II) of advanced dis-
ease (III and IV) is essential [24]. If the patient 
undergoes through surgical resection, its pa- 
thologic stage (pTNM) derived from tumor histo-
pathology and/or regional lymph nodes,  is use-
ful in the selection of postoperative adjuvant 
therapy and in order to estimate the prognosis 
[35].
Biomarkers
Until today, there is no specific biomarkers for 
oral cancer. But latest studies show that elevat-
ed levels of interleukin-8 and SAT can catego-
rize between patients with OSCC and healthy 
patients, with high sensitivity and specificity 
[36]. Predicting the malignant transformation 
of dysplasia also shown promising results. 
Recent evidence shows that a loss-of-heterozy-
gosity (LOH) status of chromosomes 3p and 9p 
is a predictive spin, high-risk lesions (3p &/or 
9p LOH) had a 20-fold increase OSCC risk com-
pared to low-risk lesions (3p & 9p retention) 
[37]. Although there are no biomarkers, neo-
plastic progression allows windows to finding 
them (Figure 2, modified from [38]).
Experimental studies for oral cancer
In addition to traditional clinical studies and 
descriptive studies of samples, assumptions 
that are related to oral cancer can be tested 
from cell lines which are originally isolated from 
patients with carcinoma and also from animal 
models of chemical carcinogenesis and trans-
genic animals. Table 3 shows some of the cell 
lines most commonly used for the experimental 
study of OSCC with an allusion to their origin 
and biological behavior (see references for 
more information: SCCs 4, 9, 15 and 25 [39-
43]; CAL27 [44]; BHY, HN and HSC-3 [45], 
HaCaT [46]). Genetic manipulation of cells 
allows silencing and overexpression of certain 
products, which can also be brought in vitro or 
in vivo (animal models). Chemical carcinogene-
sis is useful to study the progressive changes 
that occurs throughout oral carcinogenesis 
from normal tissues, through dysplastic chang-
es until the invasive carcinoma [47]. The most 
frequently used chemicals are the 9,10-dimeth-
yl-1,2-benzanthracene (DMBA) and 4-nitroquin-
oline-1 oxide (4NQO). DMBA is highly irritating 
and it has some limitations for the study of 
OSCC (it produces inflammatory response and 
necrosis of granulation tissue appearance) 
[48]. 4NQO form adducts which are similar to 
those induced by carcinogens containing snuff, 
and is more effective in inducing carcinogene-
sis and it causes extensive inflammation when 
compared with DMBA [48, 49]. Genetic app- 
roaches are particularly useful for studying the 
basics of oral cancer in its different stages and 
new therapeutic methods in a large number of 
animals by generating transgenic animals [50].
Management
The prognosis for patients with OSCC still 
remains poor, despite therapeutic advances in 
this and many other malignancies. Early diag-
nosis and treatment remains to be the  key to 
improving survival of patients [51].
Therapeutic alternatives
Among the approaches to the treatment of 
OSCC such as surgery, radiation therapy (exter-
Oral cancer
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nal beam radiotherapy and/or brachytherapy), 
and coadjutant therapy (chemotherapy with 
agents such as cisplatin, carboplatin, 5-fluoro-
uracil, paclitaxel and docetaxel) is included [16, 
52], it still remains as a high economic cost and 
highly damaging treatment/alternatives [53]. 
The OSCC is typically treated by one or a combi-
nation of these alternatives. The choice of one 
or the other depends not only on the location, 
size and stage of the primary tumor; it is also 
subjected to the comorbidities presented by 
the patient, nutritional status, its ability to toler-
ate treatment and the patient's wishes to face 
therapy [54]. In resectable tumors, surgery is 
superior to all alternative therapies [53, 55]. 
Approximately one third of patients with OSCC 
are diagnosed in stage I/II disease. The local/
regional therapy includes surgery, radiotherapy 
or a combination of both. A good prognosis for 
these patients, with cure rates of 80% (stage I) 
and 65% (stage II) is expected [56]. Unfor- 
tunately most of OSCC cases are diagnosed in 
advanced stages of disease (III or IV) [57], with 
survival at 5 years less than 50% [58] and a 
cure of 30% [55, 56]. Patients with metastatic 
disease, which are untreated show a survival of 
about 4 months [57].
Oral cancer causes substantial damage in 
speech, swallowing and chewing function, 
where pain is the main symptom. Among the 
causes of the onset or exacerbation of pain 
there are mediators in the tumor microenviron-
ment, lack of palliative therapy, a dense trigem-
inal innervation and continuous oral function, 
and pain due to treatment and opioid tolerance 
[58].
Prevention and future challenges
There is now sufficient understanding of the 
causes to prevent a third of all cancers in the 
world and it has sufficient information to enable 
early detection and well-timed treatment of 
another third of cases [59], where the OSCC 
countenances this opportunity. For oral cancer 
there is evidence that the visual examination as 
part of a population screening program reduc-
es mortality in patients at high risk [60], it is 
also possible to change lifestyles and impose 
barriers to the triggering factors. Education to 
the general population and for those with par-
ticular risk, a good theoretical basis to meet 
key aspects of oral cancer (Table 4) plus the 
constant updating in oral pathology healthcare 
providers, should be significant to decrease the 
red numbers that have accompanied this dis-
ease in recent decades. The search for specific 
biomarkers for the disease should not be aban-
doned, and future research should enable 
progress toward defining the susceptibility field 
(etiological factors and their interaction) [53], in 
order to put a stop to the story that begins with 
genetic instability keratinocytes.
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